Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Phase 2 Completed 43 enrolled Arbutus Biopharma Corporation

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.

Timeline

Start: 2021-10-29
Primary completion: 2025-03-13
Completion: 2025-05-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imdusiran	Small interfering RNA (siRNA)	60 mg	Subcutaneous
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	180 ug	Subcutaneous

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Summary

Timeline

Drugs

Indications